Products for Research Use Only

Unasnemab

CAT: 0804-HY-P99959-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99959-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) -induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS) -induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments[1][2][3].
CAS Number
2379805-59-9
Product Name Alternative
MT-3921; rH116A3
UNSPSC
12352203
Target
TGF-β Receptor
Type
Inhibitory Antibodies
Related Pathways
TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/unasnemab.html
Purity
99.00
Solubility
H2O
Smiles
[Unasnemab]
Molecular Weight
(144.88 kDa)
References & Citations
[1]Araya N, et al. Virus-induced RGMa expression drives neurodegeneration in HTLV-1-associated myelopathy. JCI Insight. 2025 Apr 24;10 (11) :e184530. |[2]Uno H, et al. Inhibition of repulsive guidance molecule A ameliorates diabetes-induced cognitive decline and hippocampal neurogenesis impairment in mice. Commun Biol. 2025 Feb 19;8 (1) :263. |[3]Yamamoto M, et al. Anti-RGMa neutralizing antibody ameliorates vascular cognitive impairment in mice. Neurotherapeutics. 2025 Mar;22 (2) :e00500.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2